SULOPENEM
Biochem/physiol Actions
Sulopenem, formerly CP-70,429, is stable to renal dehydropeptidase I and hydrolytic activity of AmpC ?-lactamases and extended-spectrum ?-lactamases (ESBLs) that convey resistance to third-generation cephalosporins. This action of sulopenem helps to act against urgentdrug-resistant antimicrobial threats, including ESBL-producing Enterobacteriaceae. Sulopenem is effective than ciprofloxacin for treating urogenital upper urinary tract infection (uUTI) in adult women due to quinolone non-susceptible pathogens.
Sulopenem is an orally available penem antibiotic designed to treat Gram-negative multi-drug resistant infections. It can be administered as an intravenous preparation, and it is also orally available.
Legal Information
Pfizer is a registered trademark of Pfizer, Inc.
Sold for research purposes under agreement from Pfizer Inc.
| Colour | white to beige |
|---|---|
| InChI key | FLSUCZWOEMTFAQ-JNCILSLHSA-N |
| InChI | 1S/C12H15NO5S3/c1-5(14)7-9(15)13-8(11(16)17)12(20-10(7)13)19-6-2-3-21(18)4-6/h5-7,10,14H,2-4H2,1H3,(H,16,17)/t5-,6?,7+,10-,21?/m1/s1 |
| Manufacturer | SIGMA-ALDRICH |
| Form | powder |
| Assay | ≥98% (HPLC) |
There are no downloads for this product.
